Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company specializing in molecular glue degrader (MGD)-based medicines, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Markus Warmuth, M.D., will deliver a presentation on Tuesday, January 14, 2025, at 5:15 p.m. PST.

The presentation will be accessible through a webcast via the 'Events & Presentations' section of Monte Rosa's investor relations website at ir.monterosatx.com. An archived version of the presentation will remain available for 30 days following the event.

News Market Reaction

-3.91%

1 alert

-3.91% News Effect

On the day this news was published, GLUE declined 3.91%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PST.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When is Monte Rosa Therapeutics (GLUE) presenting at the 2025 J.P. Morgan Healthcare Conference?

Monte Rosa Therapeutics (GLUE) will present on Tuesday, January 14, 2025, at 5:15 p.m. PST at the 43rd Annual J.P. Morgan Healthcare Conference.

How long will Monte Rosa's (GLUE) J.P. Morgan Conference presentation be available online?

The archived version of Monte Rosa's presentation will be available for 30 days following the January 14, 2025 presentation.

Where can investors access Monte Rosa's (GLUE) J.P. Morgan Healthcare Conference presentation?

Investors can access the presentation webcast through the 'Events & Presentations' section of Monte Rosa's website at ir.monterosatx.com.

What type of medicines does Monte Rosa Therapeutics (GLUE) develop?

Monte Rosa Therapeutics develops novel molecular glue degrader (MGD)-based medicines as a clinical-stage biotechnology company.